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Department of Pharmacology, College of Pharmacy, and Department of Medicine, College of
Medicine, The University of Toledo, Toledo, OH 43614
Abstract
In this review, we will discuss several well-accepted signaling pathways toward calcium-mediated
mechanisms of cystic expansion. The second messenger calcium ion has contributed to a vast
diversity of signal transduction pathways. We will dissect calcium signaling as a possible
mechanism that contributes to renal cyst formation. Because cytosolic calcium also regulates an
array of signaling pathways, we will first discuss cilia-induced calcium fluxes, followed by Wnt
signaling that has attributed to much-discussed planar cell polarity. We will then look at the
relationship between cytosolic calcium and cAMP as one of the most important aspects of cyst
progression. The signaling of cAMP on MAPK and mTOR will also be discussed. We infer that
while cilia-induced calcium fluxes may be the initial signaling messenger for various cellular
pathways, no single signaling mediator or pathway is implicated exclusively in the progression of
the cystic expansion.
Introduction
Polycystic kidney disease (PKD) is characterized by formation of fluid-filled cysts. For the
past decade, many ideas and much hard work have been put forth to understand the disease,
although the mechanisms of cyst formation and expansion remain speculations. Based on
transmittance, PKD can be simply classified into acquired and hereditary forms. The
acquired form of PKD can be found in patients who have had acute renal failure with
subsequent dialysis. The majority of PKD cases, however, are transmitted hereditarily from
the parents. The two most common hereditary forms of PKD are autosomal dominant PKD
(ADPKD) and autosomal recessive PKD (ARPKD). The genes mutated in ADPKD include
PKD1 and PKD2, whereas ARPKD is caused by mutation in PKHD1 gene (OMIMs:
#601313, 613095, 263200). The prevalence of ADPKD and ARPKD is 1 in 1,000 and 1 in
20,000 live births, respectively.
The products encoded by these PKD genes are called cysto-proteins (Figure 1), which
include polycystin-1 (PKD1), polycystin-2 (PKD1), and fibrocystin (PKHD1). Though the
mechanism of cyst formation is still a mystery, abnormal function of these proteins results in
cyst formation. In particular, cysto-proteins interact with one another (Figure 1). Thus,
aberrant functions in any of these cysto-proteins may result in similar pathogenic
phenotypes in the kidney, liver, pancreas and possibly other organs. In addition, these three
proteins are localized within the same subcellular domain in the cell. Because these proteins
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are localized and have distinct functions in the primary cilia, ciliary hypothesis has been
developed to explain a unifying pathogenic concept for PKD.
In this review, we will discuss calcium signaling as a possible mechanism that contributes to
the functions of these cysto-proteins. Dysfunction of any of these proteins may thus interrupt
calcium signaling pathways, which may promote abnormal downstream signal transductions
of various signaling molecules participating in renal cyst formation.
Calcium signaling by primary cilia
When the PKD genes were discovered and cloned [1-3], their functions in cation transport
immediately became of considerable interest in understanding the molecular functions of the
cysto-proteins. In particular, sequence analysis of polycystin-2 showed putative homologies
with other known calcium channels [4]. In addition to their physical and functional
interactions with other calcium-regulated proteins [5-7], interactions of cysto-proteins with
other calcium channels also provided further insights into the modulation of intracellular
calcium signaling [8-12]. Thus, polycystin-2 has long been predicted to regulate cytosolic
calcium [13,14], including modulating intraorganellar calcium release [15] and extracellular
calcium influx [16].
To function as a calcium channel, polycystin-2 depends on its interaction with polycystin-1
[16,17]. Likewise, proper function of fibrocystin depends on the indirect interaction with the
polycystin complex [18-20]. In addition, activation of polycystin-2 has been found to
depend on its interaction with mammalian diaphanous-related forming 1 (mDia1). mDai1 is
able to regulate polycystin-2 depending on the membrane potential or voltage levels in the
cells. At resting potentials, mDai1 in an autoinhibited state binds to polycystin-2 thereby
inhibiting its channel activity. However, at positive potentials, GTP-bound mDia1 releases
and thereby allows activation of polycystin-2 [21].
Localization of cysto-proteins to primary cilia further confirms the roles of polycystins and
fibrocystin in intracellular calcium signaling. In addition, it further elaborates the molecular
functions of cysto-proteins as regulators for intracellular calcium signaling. Most important
are the mechanosensory functions of cysto-proteins that have been independently described
in the mouse and human kidney epithelia [20,22-27], vascular endothelia [28-30],
osteochondrocytes [31,32], cholangiocytes [33,34] and developing nodes [35-37]. It is now
generally accepted that localization of these cysto-proteins to the primary cilia is important
and necessary to initiate the first signaling cascade of intracellular calcium [38-40]. This
signaling pathway may further provide other complex downstream signaling pathways.
In general, primary cilia are mechanosensory compartments that house many sensory
proteins, including the cysto-proteins. Shear stress that produces enough drag force on the
cell surface is able to bend the primary cilium (Figure 2). Subsequently, activation of the
polycystins and other interacting proteins in this complex may result in cytosolic calcium
increase. This paradigm was established based mainly on in vitro studies where cultured
kidney cells were challenged with a fluid-flow shear stress [41,42]. The ex vivo experiments
using isolated gastrulation stage node, perfused tubules and arteries have further confirmed
the mechanosensory function of the primary cilium [28,36,43]. In the vascular artery [28],
the influx of extracellular calcium initiates the biochemical cascades that lead to production
of nitric oxide vasodilator through endothelial nitric oxide (eNOS). This activation of eNOS
depends on the contribution or activity of calmodulin, phosphoinositide kinase-3, protein
kinase B and calcium-dependent protein kinase (Figure 3).
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In the next sections, we will discuss the downstream pathways that depend, directly or
indirectly, on the initial calcium signaling. Because of the complexity in calcium signaling,
we will discuss only those pathways that have possible relevance to renal cyst expansion.
Signaling by Wnt
Wnt signaling pathways are involved in many aspects of cell development, such as cell
polarity determination, cell adhesion, growth, motility, and many others. The Wnt pathway
involves a daunting number of secreted Wnt ligands and Frizzled receptors that regulate a
large number of Wnt signaling molecules. In the simplest terms, Wnt signaling can activate
three distinct pathways (Figure 4): 1) β-catenin dependent canonical pathway, 2) β-catenin
independent non-canonical or PCP (planar cell polarity) pathway, and 3) Wnt-calcium
pathway, which can influence both the canonical and non-canonical pathways[44].
Many regulatory proteins involved in Wnt signaling are localized in the primary cilium and
base of the cilium, also known as a basal body. It is thus speculated that flow-induced
cytosolic calcium influx switches off the canonical Wnt pathway and activates the non-
canonical Wnt/calcium signaling pathway (Figure 4). This molecular switch is regulated by
inversin, which is a ciliary protein that can turn different Wnt signaling pathways on and off
[45]. Of note is that abnormalities in inversin function result in polycystic kidney phenotype.
The zebrafish cystic kidney gene seahorse has also been found to be involved in a variety of
cilia-mediated processes such as body curvature, kidney cyst formation, left-right
asymmetry, and others including PCP signaling and inhibition of the canonical Wnt
signaling [46]. Seahorse seems to be essential for a functional non-canonical Wnt signaling.
It associates with Dishevelled (Dsh), the divergence point for the canonical Wnt and PCP
pathways. The Seahorse gene encodes a highly conserved five leucine-rich repeats (LRR)
and a leucine-rich repeat cap, from Drosphila to humans. One of the leucine-rich repeat
proteins, LRRC50, has been found to be conserved in both zebrafish and humans. Lrrc50 in
expressed in all ciliated tissues in zebrafish, resulting in cilary dysfunction in lrrc50
mutants. In humans and dog kidney cells, LRRC50 has been shown to localize at the mitotic
spindle and cilium, implying it to be a ciliary protein in vertebrates [47].
It is generally accepted that Wnt signaling pathway is not regulated properly in polycystic
kidney disease (Figure 4). In the canonical Wnt pathway, β-catenin in the nucleus mediates
many gene induction events, and any deregulation of this pathway can result in uninhibited
proliferation of cells [48,49]. It is speculated that flow-induced cytosolic calcium influx is
required to turn off the canonical Wnt pathway and activate the non-canonical Wnt/calcium
signaling pathway. As such, over-activation of canonical Wnt pathway, by over-production
of an activated form of β-catenin for an example, would result in polycystic kidney
phenotype [50]. This view is consistent with the profiling gene expression study [51]. A
consistently high level of Wnt signaling is observed in cystic tissues from ADPKD patients,
but not in tissues which exhibited low level or no cyst formation from the same patients.
Furthermore, abnormalities in polycystins enhance activity of Wnt signaling pathway
[52-55].
E-cadherin is one of the interacting Wnt signaling molecules, and it plays an essential role in
intercellular cell junction assembly. It is required for epithelial polarity and tubule
formation. Disruption of E-cadherin could lead to abnormal levels of β-catenin and
impeding renal epithelial polarization [54,56]. Furthermore, the protein complex of
polycystins, E-cadherin, and β-catenin is interrupted in cyst-lining epithelial cells from
ADPKD patients [57]. In addition, the levels of β-catenin in the developing hearts and
kidneys of Pkd1-/- mouse embryos compared to wild type embryos is decreased [53].
Overall, the data suggest that interruption in Wnt signaling pathway would result in less
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differentiated epithelial cells, yielding to proliferation and acceleration of cyst expansion
[58].
Planar cell polarity, which involves non-canonical Wnt signaling, has recently been the most
discussed topic toward understanding of renal cysts. Planar cell polarity is principally
involved in the development of tissue architectures along a parallel axis, other than the
apical-basolateral axis of a renal tubule (Figure 5). Oriented cell division is thought to be
necessary for the elongation of the developing nephron. Abnormalities in the planar cell
polarity, as reflected by the mitotic spindle, have been observed in various PKD mouse
models [52,59-63]. In these studies, cell division or mitotic spindle orientation within the
tubular axis were measured. However, it is currently unclear whether such an alignment can
be considered a process toward planar cell polarity [64]. In Drosophila, for example, mitotic
spindle alignment is achieved only after centrosomes have been properly aligned [65]. Thus,
there is a cell-cycle checkpoint for centrosomal positioning. The question remains whether
such a checkpoint is disrupted in PKD.
Within the non-canonical Wnt signaling, there is also a huge body of evidence indicating
that JNK signaling system is involved in PKD [66-70]. The strongest evidence of non-
canonical Wnt signaling, however, came from a study involving Rho small G protein. In the
mouse model, mutation in the key regulator of Rho small G protein results in cystic kidney
phenotype [71]. Taken together, interruption in Wnt signaling pathway would result in cyst
formation due to planar cell polarity defects, and mitotic spindle orientation might be a
contributing factor in the process.
Signaling by cAMP / MAPK
Cyclic adenosine monophosphate, or cAMP, has been identified as one of the most
important players in cyst progression in both ADPKD and ARPKD (Figure 6). Two major
processes that contribute to the expansion of the renal cysts in polycystic kidney disease are
cell proliferation and fluid secretion. cAMP is intimately involved in accelerating both of
these processes [72-75]. Tissues from the kidneys, liver, and vascular smooth muscles of
PKD animal models exhibit increased levels of cAMP [76-78].
cAMP is known to be one of most important players in effecting hormonal activation of
intracellular pathways and is intimately involved in cell proliferation in almost all cell lines.
However, cAMP does not produce the same effects in all cell lines. Though cAMP has been
used for several years as an anti-proliferative agent [79,80], cAMP has also been known to
stimulate cell proliferation by activating the mitogen activated protein kinase (MAPK)
pathway (Figure 6). For example, cAMP is anti-proliferative in normal tissues, but it
stimulates cell proliferation in cystic epithelial cells [73,81,82].
The change in cAMP related phenotype - inhibition of cell proliferation in normal cells and
stimulation of cell proliferation in cystic cells - is associated with the amount of intracellular
calcium in PKD tissues and cells [82,83]. The imbalance in the cytosolic calcium due to the
disruptions in the cysto-proteins promotes abnormal function of phosphodiesterase (Figure
6). Phosphodiesterase 1 isoforms (PDE1a, PDE1b and PDE1c) are present in especially high
levels in the kidneys [84]. Most importantly, the activity of this phosphodiesterase is
regulated by intracellular calcium and cAMP. In PKD cells with a low level of intracellular
calcium, phosphodiesterase activity is down-regulated. This results in aberrant conversion of
cAMP to AMP. The resulting increase in cytosolic cAMP further stimulates the MAPK
pathways, whichpromotes cyst expansion through higher cell proliferation.
In general, cystic epithelia in polycystic kidneys have exhibited high levels of both cAMP
and MAPK activity compared to normal cells, resulting in cell proliferation in polycystic
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kidneys and an inhibition of cell proliferation in normal cells [85,86]. In normal epithelial
cells, cAMP agonists inhibit MAPK pathway by blocking activation of Raf-1 (Raf-C)
through cAMP-dependent protein kinase (PKA). On the other hand, cAMP was found to
stimulate the MAPK pathway in PKD cells, thereby stimulating cell proliferation. This
difference has also been observed to result from an increased affinity of cAMP for B-Raf
rather than A-Raf and Raf-1 (C-Raf) [82,86]. As mentioned earlier, this change in cAMP-
related signaling is also attributed to the level of intracellular calcium. The high levels of
cAMP, combined with low levels of calcium fluxes in polycystic kidneys, could further
result in a decrease of PI3K/Akt activity, thereby stimulating B-Raf activation and hence
activation of the MAPK pathway of Ras/B-Raf/MEK/ERK [83,87,88].
Signaling by mTOR
The Ras/Raf/ERK pathway plays another important role in polycystic kidney disease by
regulating the mammalian target of rapamycin (mTOR) pathway through molecular
signaling of tuberin (Figure 7). Tuberin, which is also regulated by Akt, is a GTPase
activating protein (GAP). Tuberin regulates the activity of Rheb, a small G-protein
belonging to the Ras super family. GTP-bound Rheb is active, while GDP-bound Rheb is
inactive. Hamartin and tuberin form a heterodimer which converts Rheb-GTP to Rheb-GDP,
thereby inactivating Rheb. Rheb activates mTOR pathway. Hence, tuberin inactivates GTP-
bound Rheb and inhibits the mTOR pathway [89-91].
The respective protein products of TSC1 and TSC2, hamartin and tuberin, regulate formation
of primary cilia [92,93]. Most importantly, however, analysis of normal and diseased cells
from ADPKD patients indicates that the cyst lining epithelial cells exhibit higher levels of
mTOR signaling compared to the surrounding normal epithelium [94]. When mTOR
pathway is inhibited with rapamycin, many murine models of ADPKD and ARPKD show a
decrease in renal cyst expansion [94-100]. The consensus is that the cytoplasmic tail of
polycystin-1 directly or indirectly interacts with both mTORC1 complex as well as tuberin,
the protein product of Tsc2 which itself regulates mTORC1. Membrane localization of
polycystin-1 and hamartin are therefore able to bind to tuberin, keeping it near the plasma
membrane. Thus, membrane bound polycystin-1 is capable of controlling mTORC1
pathway and hence extensive cell proliferation. Disruption of polycystin-1 would imply the
activation of the mTORC1 cascade yielding cell proliferation and subsequent cyst formation
[101,102].
In addition, the cysto-proteins are known to contribute to the activation of the Akt/PKB
pathway [101,103,104]. Thus, the interaction of Akt and tuberin can further provide an
additional regulation of mTOR pathway by the cysto-proteins. Although the role of calcium
in mTOR signaling has still not been properly studied in polycystic kidney disease, there is a
possibility that calcium-ERK-mTOR pathway could exist. In particular, calcium is known to
be associated with cAMP/ERK activity (Figure 6), and ERK has been implicated in mTOR
signaling (Figure 7). There is no doubt that further studies are needed to dissect the
contributions of calcium, ERK and mTOR in cystogenesis.
Interestingly, clinical trials of mTOR inhibitors in ADPKD patients have not yielded a much
anticipated results [105-107]. The two mTOR inhibitors tested in ADPKD patients were
sirolimus and everolimus. Sirolimus was tested on 100 patients (18 to 40 years) exhibiting
early stages of the disease, while everolimus was tried on 433 patients in advanced-stage II
and III, with a renal baseline volume of 1500 mL. Sirolimus did not show any decrease in
total kidney size in humans, though it showed promising results in mouse models. However,
the animals were treated with a dose of 5 mg/kg of body weight [94], a dosage that is unsafe
for humans, who were administered 2 mg sirolimus for 18 months. No difference in GFR
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was observed as these patients exhibited the initial stages of the disease [105]. Everolimus,
on the other hand, slowed the increase in the total kidney volume without any effect on
GFR. After a brief transient period, patients exhibited a rapid decline in GFR [106]. These
studies imply that reducing the cyst size need not necessarily improve renal function in these
patients.
Prospective
Cilia function and structure are important and necessary to maintain the architecture of
kidney tissue. Abnormalities in the structure or function of cilia results in PKD. The
mechanosensory cilia are crucial in maintaining intracellular calcium signaling. Many cell
types, including renal epithelia, use cytosolic calcium as a second messenger to further
regulate other cellular homeostasis through a very complex signal transduction system. This
signaling system includes Wnt, cAMP - MAPK, Akt, mTOR, and other pathways that are
not discussed in this review.
In understanding this complexity, an important lesson is that no single signaling mediator is
implicated exclusively in the progression of the cystic expansion. Rather, all of these
signaling pathways are intimately connected, thereby regulating the progression of the
disease. Nonetheless, only by understanding such a complicated system do we have better
insights to attain the most effective way to retard progression of polycystic kidney disease.
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Figure 1. Cysto-protein complex
Polycystin-1 and polycystin-2 form a complex with each other at their COOH termini.
Functioning as an adaptor protein, Kif bridges the interaction of between fibrocystin and
polycystin complex. Figure is reproduced from Kolb, et al with permission [39].
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Figure 2. Primary cilia in signal transduction system
Cilia sense fluid-shear stress on the apical membrane of the cells. Fluid flow that produces
enough drag-force on the top of the cells will bend sensory cilia. Bending of cilia will
activate the cysto-proteins, resulting in extracellular calcium influx. Figure is reproduced
from AbouAlaiwi, et al with permission [38].
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Figure 3. Mechanosensory cilia, cytosolic calcium and nitric oxide production
Bending or activation of the cilia involves mechanosensory polycystin-1 and polycystin-2
complex, which results in biochemical synthesis of NO. The signaling pathway requires
extracellular calcium influx (Ca2+), followed by activation of various calcium-dependent
proteins including calmodulin (CaM) and protein kinase C (PKC). Together with PKB, CaM
and PKC are important downstream molecular components to activate endothelial nitric
oxide synthase (eNOS).
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Figure 4. Mechanosensory cilia, cytosolic calcium and Wnt signaling
Bending or activation of the cilia results in maintaining cytosolic calcium (Ca2+), followed
by activation of inversin. Calcium and inversin function as the molecular switches for Wnt
signaling pathways. The Wnt canonical pathway involves β-catenin. Both β-catenin and E-
cadherin regulate cell differentiation and proliferation. The Wnt non-canonical pathway
involves small GTPase rho and JNK, both of which play an important role in planar cell
polarity.
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Figure 5. Planar cell polarity and cystic kidney disease
The illustration depicts the mechanism of mitotic spindle formation as an index of planar
cell polarity in cyst expansion. a. Each cilium senses changes in urine flow. This message
provides critical calcium signals to the cell. b. Abnormalities in any of the cysto-proteins
results in abnormal ciliary function. c. The functional abnormality in ciliary sensing results
in disorientation of the mitotic spindle, and hence the cell will lose planar cell polarity. d.
Direction of cell division becomes randomized. This will result in increasing tubular
diameter, rather than tubular elongation. e. Budding of a cyst from the renal tubule occurs.
The abnormal localizations of epidermal growth factor receptor (EGFR) and Na+/K+
ATPase pump are typical characteristics of polycystic kidneys. f. The cyst is eventually
enlarged and expanded further. Multiple cysts within a kidney are illustrated on the bottom
left corner. Figure is reproduced from Kolb, et al with permission [39].
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Figure 6. Cytosolic calcium and cAMP signaling
Under normal conditions, the carboxy terminal tails of polycystin-1 and polycystin-2
interact, which enables calcium entry into the cell. This further stimulates the release of
calcium from the calcium stores inside the cell. In the presence of high, steady state levels of
calcium, calcium-stimulated phosphodiesterases are capable of degrading cAMP into AMP,
thereby controlling the cAMP levels in the cell. The low levels of cAMP are unable to
stimulate MAPK pathway. In polycystic kidneys, however, the resulting abnormality in
cysto-proteins causes a lower level of intracellular calcium. Hence, the activity of
phosphodiesterases is not stimulated and cAMP level increases, leading to activation of B-
Raf of MAPK pathway.
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Figure 7. Signaling pathway of mTOR
In healthy kidney cells, the cysto-protein complex interacts with tuberin. Hamartin and
tuberin form a complex and localize in the basal body. Tuberin is a GTPase activating
protein (GAP) which controls the activity of Rheb. Tuberin inactivates Rheb, thereby
inhibiting the mTOR pathway. In polycystic kidneys, however, tuberin is no longer
protected in this complex and is phosphorylated by Akt, RSK (via ERK). As a result, tubulin
is unable to form a heteradimer with hamartin. Hence, tuberin is no longer able inhibit Rheb,
and the mTOR pathway is activated.
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